September 19, 2021

Feng Zhang unveils a new technology to potentially deliver mRNA, gene therapy, CRISPR and more – Endpoints News

After hitting just about every pothole with its Covid-19 vaccine rollout, AstraZeneca has some good news to share for another pandemic-related program: Its monoclonal antibody combo, AZD7442, proved effective at preventing symptomatic Covid-19 in a Phase III study.

AZD7442 reduced the risk of symptomatic Covid-19 by 77%, based on a preliminary group of cases in a large, global Phase III trial, according to the British pharma. The study, dubbed PROVENT, enrolled nearly 5,200 volunteers across the US, UK, Spain, France and Belgium, 75% of whom had comorbidities or conditions that would cause a reduced immune response to vaccination.

Read full article here: